OSmfs: An Online Interactive Tool to Evaluate Prognostic Markers for Myxofibrosarcoma

Genes (Basel). 2020 Dec 19;11(12):1523. doi: 10.3390/genes11121523.

Abstract

Myxofibrosarcoma is a complex genetic disease with poor prognosis. However, more effective biomarkers that forebode poor prognosis in Myxofibrosarcoma remain to be determined. Herein, utilizing gene expression profiling data and clinical follow-up data of Myxofibrosarcoma cases in three independent cohorts with a total of 128 Myxofibrosarcoma samples from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, we constructed an easy-to-use web tool, named Online consensus Survival analysis for Myxofibrosarcoma (OSmfs) to analyze the prognostic value of certain genes. Through retrieving the database, users generate a Kaplan-Meier plot with log-rank test and hazard ratio (HR) to assess prognostic-related genes or discover novel Myxofibrosarcoma prognostic biomarkers. The effectiveness and availability of OSmfs were validated using genes in ever reports predicting the prognosis of Myxofibrosarcoma patients. Furthermore, utilizing the cox analysis data and transcriptome data establishing OSmfs, seven genes were selected and considered as more potentially prognostic biomarkers through overlapping and ROC analysis. In conclusion, OSmfs is a promising web tool to evaluate the prognostic potency and reliability of genes in Myxofibrosarcoma, which may significantly contribute to the enrichment of novelly potential prognostic biomarkers and therapeutic targets for Myxofibrosarcoma.

Keywords: Myxofibrosarcoma; OSmfs; prognostic markers; tool.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Area Under Curve
  • Base Sequence
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / genetics*
  • Datasets as Topic
  • Fibroma / chemistry
  • Fibroma / genetics*
  • Fibroma / mortality
  • Fibrosarcoma / chemistry
  • Fibrosarcoma / genetics*
  • Fibrosarcoma / mortality
  • Gene Ontology
  • Humans
  • Internet*
  • Kaplan-Meier Estimate
  • Prognosis
  • Proportional Hazards Models
  • ROC Curve
  • Software*
  • Survival Analysis

Substances

  • Biomarkers, Tumor